146 related articles for article (PubMed ID: 22361489)
1. Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9.
Mukherjee AK; Gupta G; Adhikari A; Majumder S; Kar Mahapatra S; Bhattacharyya Majumdar S; Majumdar S
Int Immunopharmacol; 2012 Apr; 12(4):565-72. PubMed ID: 22361489
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
[TBL] [Abstract][Full Text] [Related]
3. Leishmania donovani influenced cytokines and Toll-like receptors expression among Sudanese visceral leishmaniasis patients.
Babiker DT; Bakhiet SM; Mukhtar MM
Parasite Immunol; 2015 Aug; 37(8):417-25. PubMed ID: 25982946
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B regulates the host immune response in visceral leishmaniasis: reciprocal regulation of protein kinase C isoforms.
Mukherjee AK; Gupta G; Bhattacharjee S; Guha SK; Majumder S; Adhikari A; Bhattachrya P; Majumdar SB; Majumdar S
J Infect; 2010 Jul; 61(2):173-84. PubMed ID: 20546775
[TBL] [Abstract][Full Text] [Related]
5. Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro.
Das S; Rani M; Pandey K; Sahoo GC; Rabidas VN; Singh D; Das P
J Antimicrob Chemother; 2012 Oct; 67(10):2373-8. PubMed ID: 22761329
[TBL] [Abstract][Full Text] [Related]
6. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
[TBL] [Abstract][Full Text] [Related]
7. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
8. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis.
Mukhopadhyay D; Das NK; Roy S; Kundu S; Barbhuiya JN; Chatterjee M
J Infect Dis; 2011 Nov; 204(9):1427-36. PubMed ID: 21933878
[TBL] [Abstract][Full Text] [Related]
9. Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.
Shivahare R; Vishwakarma P; Parmar N; Yadav PK; Haq W; Srivastava M; Gupta S; Kar S
PLoS One; 2014; 9(4):e94596. PubMed ID: 24732039
[TBL] [Abstract][Full Text] [Related]
10. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
[TBL] [Abstract][Full Text] [Related]
11. Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
Gangalum PR; de Castro W; Vieira LQ; Dey R; Rivas L; Singh S; Majumdar S; Saha B
J Immunol; 2015 Jun; 194(12):5961-7. PubMed ID: 25980013
[TBL] [Abstract][Full Text] [Related]
12. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
Shakya N; Sane SA; Vishwakarma P; Gupta S
Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
[TBL] [Abstract][Full Text] [Related]
13. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
14. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
15. NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs.
Schleicher U; Liese J; Knippertz I; Kurzmann C; Hesse A; Heit A; Fischer JA; Weiss S; Kalinke U; Kunz S; Bogdan C
J Exp Med; 2007 Apr; 204(4):893-906. PubMed ID: 17389237
[TBL] [Abstract][Full Text] [Related]
16. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis.
Das S; Rani M; Rabidas V; Pandey K; Sahoo GC; Das P
Br J Pharmacol; 2014 Mar; 171(5):1260-74. PubMed ID: 24670148
[TBL] [Abstract][Full Text] [Related]
17. Mycobacterium indicus pranii (Mw)-mediated protection against visceral leishmaniasis: involvement of TLR4 signalling.
Adhikari A; Majumder S; Banerjee S; Gupta G; Bhattacharya P; Majumdar SB; Saha B; Majumdar S
J Antimicrob Chemother; 2012 Dec; 67(12):2892-902. PubMed ID: 22879460
[TBL] [Abstract][Full Text] [Related]
18. Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.
Shivahare R; Ali W; Vishwakarma P; Natu SM; Puri SK; Gupta S
Acta Trop; 2015 Oct; 150():35-41. PubMed ID: 26119043
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients.
Das S; Pandey K; Rabidas VN; Mandal A; Das P
J Antimicrob Chemother; 2013 Sep; 68(9):2059-65. PubMed ID: 23729024
[TBL] [Abstract][Full Text] [Related]
20. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
